RAPT Therapeutics Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for RAPT Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RAPT Therapeutics stock.
View analyst ratings for RAPT Therapeutics or view top-rated stocks.

Wall Street analysts have given RAPT Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but RAPT Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

RAPT Therapeutics saw a drop in short interest during the month of January. As of January 29th, there was short interest totaling 814,500 shares, a drop of 28.6% from the January 14th total of 1,140,000 shares. Based on an average daily trading volume, of 427,300 shares, the days-to-cover ratio is presently 1.9 days. Approximately 5.2% of the shares of the stock are sold short.
View RAPT Therapeutics' Short Interest.

RAPT Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 29th 2021.
View our earnings forecast for RAPT Therapeutics.

RAPT Therapeutics, Inc. (NASDAQ:RAPT) announced its quarterly earnings data on Sunday, November, 15th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.56) by $0.04. The firm earned $1.53 million during the quarter, compared to analysts' expectations of $2.50 million.
View RAPT Therapeutics' earnings history.

RAPT Therapeutics' stock was trading at $15.73 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, RAPT shares have increased by 9.1% and is now trading at $17.16.
View which stocks have been most impacted by COVID-19.

5 equities research analysts have issued 12 month target prices for RAPT Therapeutics' shares. Their forecasts range from $30.00 to $51.00. On average, they anticipate RAPT Therapeutics' stock price to reach $40.80 in the next twelve months. This suggests a possible upside of 137.8% from the stock's current price.
View analysts' price targets for RAPT Therapeutics or view top-rated stocks among Wall Street analysts.

8 employees have rated RAPT Therapeutics CEO Brian Wong on Glassdoor.com. Brian Wong has an approval rating of 100% among RAPT Therapeutics' employees. This puts Brian Wong in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to RAPT Therapeutics include Amneal Pharmaceuticals (AMRX), Ironwood Pharmaceuticals (IRWD), Organogenesis (ORGO), Seres Therapeutics (MCRB), Aurinia Pharmaceuticals (AUPH), ADC Therapeutics (ADCT), Travere Therapeutics (TVTX), Zentalis Pharmaceuticals (ZNTL), Kronos Bio (KRON), Heron Therapeutics (HRTX), PMV Pharmaceuticals (PMVP), Y-mAbs Therapeutics (YMAB), Zymeworks (ZYME), Shattuck Labs (STTK) and Arcutis Biotherapeutics (ARQT).
View all of RAPT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other RAPT Therapeutics investors own include NVIDIA (NVDA), The Boeing (BA), Slack Technologies (WORK), Overstock.com (OSTK), salesforce.com (CRM), Enphase Energy (ENPH), Inovio Pharmaceuticals (INO), Livongo Health (LVGO), Mastercard (MA) and QUALCOMM (QCOM).

(RAPT) raised $39 million in an initial public offering (IPO) on Thursday, October 31st 2019. The company issued 3,000,000 shares at $12.00-$14.00 per share. BMO Capital Markets, Wells Fargo Securities and UBS Investment Bank served as the underwriters for the IPO.

RAPT Therapeutics trades on the NASDAQ under the ticker symbol "RAPT."

RAPT Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (10.53%), BlackRock Inc. (5.64%), Regents of The University of California (4.57%), Acuta Capital Partners LLC (0.85%), Northern Trust Corp (0.61%) and Charles Schwab Investment Management Inc. (0.27%). Company insiders that own RAPT Therapeutics stock include Brian Russell Wong, Dirk G Brockstedt, Group Ii Lp Column, Karen C Lam, Michael F Giordano, Peter Svennilson, Wendye Robbins and William Ho.
View institutional ownership trends for RAPT Therapeutics.

RAPT stock was sold by a variety of institutional investors in the last quarter, including Regents of The University of California, Price T Rowe Associates Inc. MD, Acuta Capital Partners LLC, Wells Fargo & Company MN, Virtus ETF Advisers LLC, and State of Wisconsin Investment Board. Company insiders that have sold RAPT Therapeutics company stock in the last year include Brian Russell Wong, Dirk G Brockstedt, Karen C Lam, Michael F Giordano, Peter Svennilson, and William Ho.
View insider buying and selling activity for RAPT Therapeutics or view top insider-selling stocks.

RAPT stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Swiss National Bank, Squarepoint Ops LLC, Voloridge Investment Management LLC, Bank of New York Mellon Corp, QS Investors LLC, William Marsh Rice University, and Renaissance Technologies LLC. Company insiders that have bought RAPT Therapeutics stock in the last two years include Brian Russell Wong, Group Ii Lp Column, and Wendye Robbins.
View insider buying and selling activity for RAPT Therapeutics or or view top insider-buying stocks.

Shares of RAPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RAPT stock can currently be purchased for approximately $17.16.

RAPT Therapeutics has a market capitalization of $421.36 million. The company earns $-43,000,000.00 in net income (profit) each year or ($9.89) on an earnings per share basis.

RAPT Therapeutics employs 71 workers across the globe.

The official website for RAPT Therapeutics is www.rapt.com.

RAPT Therapeutics is headquartered at 561 ECCLES AVENUE, SOUTH SAN FRANCISCO CA, 94080.

RAPT Therapeutics' mailing address is 561 ECCLES AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-489-9000 or via email at [email protected]